Loading...
•
Mar 31
Olema Q1 2025 Earnings Report
Estimated Revenue:$NaN
Estimated EPS:-$0.5
+5.7% YoY
Key Takeaways
Olema Oncology reported a net loss of $30.4 million for the first quarter of 2025, a slight improvement from the $31.0 million loss in the same period last year, primarily due to higher interest income. The company ended the quarter with $392.7 million in cash, cash equivalents, and marketable securities, indicating a strong financial position to support its ongoing clinical development programs, including the pivotal Phase 3 OPERA-02 and OPERA-01 trials for palazestrant.
Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib is on track for initiation in 2025.
Pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy continues to advance with top-line data anticipated in 2026.
Preclinical data for OP-3136 demonstrated anti-tumor activity in ovarian, non-small cell lung, and prostate cancer models.
The company maintained a strong financial position, ending the quarter with $392.7 million in cash, cash equivalents, and marketable securities.
Olema
Olema
Forward Guidance
Olema Oncology anticipates continued progress in its clinical development programs, with key milestones expected in the coming years, including the initiation of the pivotal Phase 3 OPERA-02 trial and top-line data from the OPERA-01 trial.
Positive Outlook
- Initiation of pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer in 2025.
- Anticipated top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant monotherapy in 2/3L metastatic breast cancer in 2026.
- Presentation of trial-in-progress poster for OPERA-01 at the ASCO Annual Meeting in June.
- Presentation of mature data from the Phase 1b/2 trial of palazestrant in combination with ribociclib at an upcoming medical meeting.
- Continued enrollment in the Phase 1 study for OP-3136.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The company's financial performance is subject to risks and uncertainties inherent in clinical development.
- Future results could differ materially from current expectations.
- The company assumes no obligation to update forward-looking statements.
- Success of clinical trials is not guaranteed and depends on various factors.
Loading...
Key Statistics
Market Cap
$375M
P/E Ratio
-2.84
Sector
Health Technology
Industry
Pharmaceuticals Major
52-Week High
$13.6
52-Week Low
$3.05
Research and Development Expenses
$30.6M
General and Administrative Expenses
$4.2M
Non-GAAP R&D Expenses
$27.3M
Non-GAAP G&A Expenses
$3.2M